Aerie Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares rise more than 16% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $48.60 to $60.10 in the past one-month time frame.

The move came after the study shows that the company’s glaucoma treatment Rhopressa is effective in reducing eye pressure.

The company has not seen any estimate revisions over the past month and the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Aerie Pharmaceuticals currently has a Zacks Rank #4 (Sell), while its Earnings ESP is 0.00%.

A better-ranked stock in the Medical - Drugs industry is Corbus Pharmaceuticals Holdings, Inc. (CRBP Quick QuoteCRBP - Free Report) , which currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is AERI going up? Or down? Predict to see what others think: Up or Down

Wall Street’s Next Amazon

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.

Click for details >>